{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T23:28:29Z","timestamp":1793662109388,"version":"4.5.1"},"reference-count":119,"publisher":"European Respiratory Society (ERS)","issue":"178","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir Rev"],"accepted":{"date-parts":[[2025,8,4]]},"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The incidence and prevalence of disease caused by nontuberculous mycobacteria (NTM) are increasing globally, yet treatment regimens remain complex and often ineffective. Newer tetracyclines have shown promise as a potent therapeutic. In this systematic review, we assessed the evidence for the use of tetracyclines for the treatment of NTM disease, complemented by a narrative review of nonclinical data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Medline (PubMed) and Web of Science were searched from inception to February 2024 for clinical studies that assessed the safety, tolerability or efficacy of tetracyclines for NTM disease. Search results were screened against pre-defined inclusion and exclusion criteria. Nonclinical data were identified using a targeted literature search and are presented in a narrative synthesis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 89 citations were included, comprising 43 clinical studies (six prospective observational studies, 18 retrospective studies and 19 case series) and 46 nonclinical studies. Nonclinical studies demonstrated potent\n                      <jats:italic>in vitro<\/jats:italic>\n                      activity for tigecycline, omadacycline and eravacycline, particularly against rapidly growing mycobacteria (RGM). No randomised controlled trials (RCTs) were identified. Most clinical experience was for RGM (largely\n                      <jats:italic>Mycobacterium abscessus)<\/jats:italic>\n                      and supported the use of newer tetracyclines. Evidence for the treatment of slowly growing mycobacteria, particularly\n                      <jats:italic>Mycobacterium avium<\/jats:italic>\n                      complex, was more limited.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>There remains a significant unmet need for effective, well-tolerated therapies for the treatment of NTM, especially those that improve quality of life. Although tetracyclines have not been evaluated in RCTs, clinical evidence suggests that tetracyclines may contribute to the efficacy of combination regimens used to treat NTM disease and further RCTs are warranted.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1183\/16000617.0038-2025","type":"journal-article","created":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T15:05:18Z","timestamp":1762355118000},"page":"250038","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["A systematic review of tetracyclines for nontuberculous mycobacteria: focus on rapidly growing mycobacteria"],"prefix":"10.1183","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3324-926X","authenticated-orcid":false,"given":"Charles L.","family":"Daley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick A.","family":"Flume","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0581-2003","authenticated-orcid":false,"given":"Jakko","family":"van Ingen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reeti","family":"Khare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina M.","family":"Mingora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7598-7362","authenticated-orcid":false,"given":"Minh-Vu H.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin L.","family":"Winthrop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. Shoshana","family":"Zha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2025,11,5]]},"reference":[{"key":"2025110507050968000_34.178.250038.1","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.3390\/jcm9082541","article-title":"General overview of nontuberculous mycobacteria opportunistic pathogens: Mycobacterium avium and Mycobacterium abscessus","volume":"9","author":"To","year":"2020","journal-title":"J Clin Med"},{"key":"2025110507050968000_34.178.250038.2","doi-asserted-by":"crossref","first-page":"100244","DOI":"10.1016\/j.jctube.2021.100244","article-title":"Approach to the diagnosis and treatment of non-tuberculous mycobacterial disease","volume":"24","author":"Pennington","year":"2021","journal-title":"J Clin Tuberc Other Mycobact Dis"},{"key":"2025110507050968000_34.178.250038.3","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00535-2020"},{"key":"2025110507050968000_34.178.250038.4","unstructured":"US Food and Drug Administration . ARIKAYCE (amikacin liposome inhalation suspension), for oral inhalation use. Prescribing information. Date last updated: February 2023. Date last accessed: February 2024. www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/207356s012lbl.pdf"},{"key":"2025110507050968000_34.178.250038.5","unstructured":"European Medicines Agency . ARIKAYCE liposomal 590\u2005mg nebuliser dispersion SmPC. Date last updated: 2023. Date last accessed: May 2025. www.ema.europa.eu\/en\/documents\/product-information\/arikayce-liposomal-product-information_en.pdf"},{"key":"2025110507050968000_34.178.250038.6","unstructured":"ARIKAYCE . ARIKAYCE inhalation 590\u2005mg (amikacin sulfate inhalation drug product). Kusuri-no-Shiori. Date last updated: 2022. Date last accessed: May 2025. https:\/\/arikayce.jp\/data\/PI.pdf"},{"key":"2025110507050968000_34.178.250038.7","unstructured":"US Food and Drug Administration . BIAXIN Filmtab (clarithromycin tablets, USP), BIAXIN XL Filmtab (clarithromycin extended-release tablets), BIAXIN Granules (clarithromycin for oral suspension, USP). Prescribing Information. Date last accessed: May 2025. www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/050662s042,050698s024,050775s013lbl.pdf"},{"key":"2025110507050968000_34.178.250038.8","unstructured":"US Food and Drug Administration . ZITHROMAX (azithromycin) 600\u2005mg tablets, for oral use. ZITHROMAX (azithromycin) for oral suspension. Prescribing information. Date last updated: 2021. Date last accessed: May 2025. www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/050730s043,050693s034lbl.pdf"},{"key":"2025110507050968000_34.178.250038.9","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.201304-085OC"},{"key":"2025110507050968000_34.178.250038.10","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01855-2016"},{"key":"2025110507050968000_34.178.250038.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2020.08.2055"},{"key":"2025110507050968000_34.178.250038.12","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200604-571ST"},{"key":"2025110507050968000_34.178.250038.13","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2015-207360"},{"key":"2025110507050968000_34.178.250038.14","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2016-209729"},{"key":"2025110507050968000_34.178.250038.15","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(21)00586-7"},{"key":"2025110507050968000_34.178.250038.16","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01347-17"},{"key":"2025110507050968000_34.178.250038.17","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.diagmicrobio.2018.08.008","article-title":"Drug susceptibility patterns of Mycobacterium abscessus and Mycobacterium massiliense isolated from respiratory specimens","volume":"93","author":"Cho","year":"2019","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2025110507050968000_34.178.250038.18","doi-asserted-by":"crossref","first-page":"115882","DOI":"10.1016\/j.diagmicrobio.2022.115882","article-title":"In vitro susceptibility patterns for rapidly growing nontuberculous mycobacteria in the United States","volume":"105","author":"Hunkins","year":"2023","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2025110507050968000_34.178.250038.19","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00119-18"},{"key":"2025110507050968000_34.178.250038.20","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13122085"},{"key":"2025110507050968000_34.178.250038.21","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.10.3164-3167.2002"},{"key":"2025110507050968000_34.178.250038.22","doi-asserted-by":"crossref","first-page":"101484","DOI":"10.1016\/j.cegh.2023.101484","article-title":"Introduction to the GRADE tool for rating certainty in evidence and recommendations","volume":"25","author":"Prasad","year":"2024","journal-title":"Clin Epidemiol Global Health"},{"key":"2025110507050968000_34.178.250038.23","doi-asserted-by":"publisher","DOI":"10.1097\/PRS.0b013e318219c171"},{"key":"2025110507050968000_34.178.250038.24","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02522-18"},{"key":"2025110507050968000_34.178.250038.25","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01947-20"},{"key":"2025110507050968000_34.178.250038.26","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1093\/jac\/dkaa520","article-title":"In vitro susceptibility of Mycobacterium abscessus complex and feasibility of standardizing treatment regimens","volume":"76","author":"Chew","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"2025110507050968000_34.178.250038.27","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00689-22"},{"key":"2025110507050968000_34.178.250038.28","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00470-19"},{"key":"2025110507050968000_34.178.250038.29","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01704-21"},{"key":"2025110507050968000_34.178.250038.30","doi-asserted-by":"crossref","first-page":"e0323822","DOI":"10.1128\/spectrum.03238-22","article-title":"In vitro antimicrobial activities of tigecycline, eravacycline, omadacycline, and sarecycline against rapidly growing mycobacteria","volume":"11","author":"Zhang","year":"2023","journal-title":"Microbiol Spectr"},{"key":"2025110507050968000_34.178.250038.31","doi-asserted-by":"crossref","first-page":"e0071823","DOI":"10.1128\/spectrum.00718-23","article-title":"Omadacycline, eravacycline, and tigecycline express anti-Mycobacterium abscessus activity in vitro","volume":"11","author":"Li","year":"2023","journal-title":"Microbiol Spectr"},{"key":"2025110507050968000_34.178.250038.32","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2018.00932"},{"key":"2025110507050968000_34.178.250038.33","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.790767"},{"key":"2025110507050968000_34.178.250038.34","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02234-18"},{"key":"2025110507050968000_34.178.250038.35","doi-asserted-by":"crossref","first-page":"e0004521","DOI":"10.1128\/Spectrum.00045-21","article-title":"In vitro synergy testing of eravacycline in combination with clarithromycin and rifabutin against Mycobacterium abscessus complex","volume":"9","author":"Chew","year":"2021","journal-title":"Microbiol Spectr"},{"key":"2025110507050968000_34.178.250038.36","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01579-22"},{"key":"2025110507050968000_34.178.250038.37","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2012.10.021"},{"key":"2025110507050968000_34.178.250038.38","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00283-18"},{"key":"2025110507050968000_34.178.250038.39","doi-asserted-by":"publisher","DOI":"10.1111\/1469-0691.12780"},{"key":"2025110507050968000_34.178.250038.40","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01208-18"},{"key":"2025110507050968000_34.178.250038.41","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz267"},{"key":"2025110507050968000_34.178.250038.42","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1093\/jac\/dkaa110","article-title":"Inhaled tigecycline is effective against Mycobacterium abscessus in vitro and in vivo","volume":"75","author":"Pearce","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2025110507050968000_34.178.250038.43","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/s41429-020-00392-0","article-title":"Comparison of two-drug combinations, amikacin\/tigecycline\/imipenem and amikacin\/tigecycline\/clarithromycin against Mycobacteroides abscessus subsp. abscessus using the in vitro time-kill assay","volume":"74","author":"Portell-Buj","year":"2021","journal-title":"J Antibiot (Tokyo)"},{"key":"2025110507050968000_34.178.250038.44","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz523"},{"key":"2025110507050968000_34.178.250038.45","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01509-21"},{"key":"2025110507050968000_34.178.250038.46","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03112-15"},{"key":"2025110507050968000_34.178.250038.47","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2023.106847"},{"key":"2025110507050968000_34.178.250038.48","doi-asserted-by":"publisher","DOI":"10.1016\/j.mimet.2018.03.020"},{"key":"2025110507050968000_34.178.250038.49","doi-asserted-by":"crossref","first-page":"dlad104","DOI":"10.1093\/jacamr\/dlad104","article-title":"Evaluation of omadacycline against intracellular Mycobacterium abscessus in an infection model in human macrophages","volume":"5","author":"Jahanbakhsh","year":"2023","journal-title":"JAC Antimicrob Resist"},{"key":"2025110507050968000_34.178.250038.50","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jit614"},{"key":"2025110507050968000_34.178.250038.51","doi-asserted-by":"publisher","DOI":"10.1128\/msphere.00665-22"},{"key":"2025110507050968000_34.178.250038.52","doi-asserted-by":"crossref","first-page":"102306","DOI":"10.1016\/j.tube.2023.102306","article-title":"Spray dried tigecycline dry powder aerosols for the treatment of nontuberculous mycobacterial pulmonary infections","volume":"139","author":"Maloney","year":"2023","journal-title":"Tuberculosis (Edinb)"},{"key":"2025110507050968000_34.178.250038.53","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkad317"},{"key":"2025110507050968000_34.178.250038.54","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz143"},{"key":"2025110507050968000_34.178.250038.55","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02864-15"},{"key":"2025110507050968000_34.178.250038.56","first-page":"A4349","article-title":"Tiger roars: tigecycline pharmacokinetics\/pharmacodynamic (PK\/PD) based treatment of pulmonary Mycobacterium avium complex (MAC) disease","volume":"201","author":"Deshpande","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"2025110507050968000_34.178.250038.57","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkad352"},{"key":"2025110507050968000_34.178.250038.58","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00810-20"},{"key":"2025110507050968000_34.178.250038.59","doi-asserted-by":"crossref","first-page":"107423","DOI":"10.1016\/j.ijantimicag.2024.107423","article-title":"Replacing rifampicin with minocycline increases the activity of the treatment regimen for Mycobacterium avium complex pulmonary disease in a dynamic hollow-fibre system","volume":"65","author":"Raaijmakers","year":"2024","journal-title":"Int J Antimicrob Agents"},{"key":"2025110507050968000_34.178.250038.60","doi-asserted-by":"crossref","first-page":"e0068722","DOI":"10.1128\/aac.00687-22","article-title":"Omadacycline pharmacokinetics\/pharmacodynamics in the hollow fiber system model and potential combination regimen for short course treatment of Mycobacterium kansasii pulmonary disease","volume":"66","author":"Singh","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"2025110507050968000_34.178.250038.61","doi-asserted-by":"crossref","first-page":"102269","DOI":"10.1016\/j.tube.2022.102269","article-title":"Challenges and a potential solution to perform drug susceptibility testing of omadacycline against nontuberculous mycobacteria","volume":"137","author":"Shankar","year":"2022","journal-title":"Tuberculosis (Edinb)"},{"key":"2025110507050968000_34.178.250038.62","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dki386"},{"key":"2025110507050968000_34.178.250038.63","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2012.04.001"},{"key":"2025110507050968000_34.178.250038.64","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkac068"},{"key":"2025110507050968000_34.178.250038.65","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01355-09"},{"key":"2025110507050968000_34.178.250038.66","doi-asserted-by":"crossref","first-page":"e01703","DOI":"10.1016\/j.idcr.2023.e01703","article-title":"Omadacycline for the treatment of Mycobacterium abscessus infections: case series and review of the literature","volume":"31","author":"Siddiqa","year":"2023","journal-title":"IDCases"},{"key":"2025110507050968000_34.178.250038.67","doi-asserted-by":"crossref","first-page":"ofac591","DOI":"10.1093\/ofid\/ofac591","article-title":"Eravacycline associated hypofibrinogenemia: a case series of transplant patients with Mycobacterium Abscessus infections and review of literature","volume":"9","author":"Rausch","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"2025110507050968000_34.178.250038.68","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.ijid.2022.06.061","article-title":"Omadacycline in first-line combination therapy for pulmonary Mycobacterium abscessus infection: a case series","volume":"122","author":"Duah","year":"2022","journal-title":"Int J Infect Dis"},{"key":"2025110507050968000_34.178.250038.69","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/coa.13931","article-title":"Quality of life in children receiving treatment for Mycobacterium abscessus otomastoiditis","volume":"47","author":"Leow","year":"2022","journal-title":"Clin Otolaryngol"},{"key":"2025110507050968000_34.178.250038.70","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1093\/cid\/ciaa215","article-title":"Invasive Mycobacterium abscessus complex infection after cardiac surgery: epidemiology, management, and clinical outcomes","volume":"72","author":"Baker","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2025110507050968000_34.178.250038.71","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa415"},{"key":"2025110507050968000_34.178.250038.72","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01203-19"},{"key":"2025110507050968000_34.178.250038.73","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.3390\/pathogens11121399","article-title":"Atypical mycobacteriosis due to Mycobacterium abscessus subsp. massiliense: our experience","volume":"11","author":"Rodr\u00edguez-Cerdeira","year":"2022","journal-title":"Pathogens"},{"key":"2025110507050968000_34.178.250038.74","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1097\/IPC.0000000000000407","article-title":"Breast wound infections with rapidly growing mycobacteria after cancer surgery","volume":"25","author":"S\u00e1nchez-Vargas","year":"2017","journal-title":"Infect Dis Clin Pract"},{"key":"2025110507050968000_34.178.250038.75","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1086\/606050","article-title":"Clinical management of rapidly growing mycobacterial cutaneous infections in patients after mesotherapy","volume":"49","author":"Regnier","year":"2009","journal-title":"Clin Infect Dis"},{"key":"2025110507050968000_34.178.250038.76","doi-asserted-by":"crossref","first-page":"A319","DOI":"10.1016\/j.chest.2020.08.316","article-title":"Clinical experience with tigecycline-containing regimens for treatment of Mycobacterium abscessus complex and Mycobacterium chelonae infections","volume":"158","author":"Threadgill","year":"2020","journal-title":"Chest"},{"key":"2025110507050968000_34.178.250038.77","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/0266-7681(92)90199-C","article-title":"Mycobacterium fortuitum infections of the hand. Report of five cases","volume":"17","author":"Ip","year":"1992","journal-title":"J Hand Surg Br"},{"key":"2025110507050968000_34.178.250038.78","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/3.5.1068"},{"key":"2025110507050968000_34.178.250038.79","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw724"},{"key":"2025110507050968000_34.178.250038.80","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201003-0395OC"},{"key":"2025110507050968000_34.178.250038.81","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200905-0704OC"},{"key":"2025110507050968000_34.178.250038.82","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2019.01977"},{"key":"2025110507050968000_34.178.250038.83","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.chest.2023.08.025","article-title":"Outcomes of intermittent multidrug iv therapy for refractory Mycobacterium abscessus pulmonary disease","volume":"165","author":"Im","year":"2023","journal-title":"Chest"},{"key":"2025110507050968000_34.178.250038.84","doi-asserted-by":"crossref","first-page":"e0077422","DOI":"10.1128\/aac.00774-22","article-title":"Outcomes of short-term tigecycline-containing regimens for Mycobacterium abscessus pulmonary disease","volume":"66","author":"Kim","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"2025110507050968000_34.178.250038.85","doi-asserted-by":"crossref","first-page":"571","DOI":"10.3390\/antibiotics11050571","article-title":"Treatment outcome in patients with Mycobacterium abscessus complex lung disease: the impact of tigecycline and amikacin","volume":"11","author":"Yang","year":"2022","journal-title":"Antibiotics (Basel)"},{"key":"2025110507050968000_34.178.250038.86","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.rmed.2019.10.006","article-title":"Efficacy and safety of tigecycline for Mycobacterium abscessus disease","volume":"158","author":"Kwon","year":"2019","journal-title":"Respir Med"},{"key":"2025110507050968000_34.178.250038.87","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.201508-529OC"},{"key":"2025110507050968000_34.178.250038.88","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dku062"},{"key":"2025110507050968000_34.178.250038.89","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofad335"},{"key":"2025110507050968000_34.178.250038.90","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00824-23"},{"key":"2025110507050968000_34.178.250038.91","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/152.3.500"},{"key":"2025110507050968000_34.178.250038.92","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.15.4.716-746.2002"},{"key":"2025110507050968000_34.178.250038.93","doi-asserted-by":"publisher","DOI":"10.1099\/00207713-42-2-240"},{"key":"2025110507050968000_34.178.250038.94","doi-asserted-by":"publisher","DOI":"10.1086\/380459"},{"key":"2025110507050968000_34.178.250038.95","first-page":"462","article-title":"Clarithromycin with minocycline and clofazimine for Mycobacterium avium intracellulare complex lung disease in patients without the acquired immune deficiency syndrome. GETIM. Groupe d'Etude et de Traitement des Infections \u00e0 Mycobact\u00e9ries","volume":"2","author":"Roussel","year":"1998","journal-title":"Int J Tuberc Lung Dis"},{"key":"2025110507050968000_34.178.250038.96","doi-asserted-by":"publisher","DOI":"10.1378\/chest.107.4.1035"},{"key":"2025110507050968000_34.178.250038.97","doi-asserted-by":"crossref","first-page":"ofac077","DOI":"10.1093\/ofid\/ofac077","article-title":"Treatment and outcome of culture-confirmed Mycobacterium marinum disease","volume":"9","author":"Hendrikx","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"2025110507050968000_34.178.250038.98","first-page":"1211","article-title":"Diagnosis and therapy of Mycobacterium marinum: a single-center 21-year retrospective analysis","volume":"20","author":"Strobel","year":"2022","journal-title":"J Dtsch Dermatol Ges"},{"key":"2025110507050968000_34.178.250038.99","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0041296"},{"key":"2025110507050968000_34.178.250038.100","first-page":"197","article-title":"Multicenter study of incidence of Mycobacterium marinum in humans in Spain","volume":"5","author":"Casal","year":"2001","journal-title":"Int J Tuberc Lung Dis"},{"key":"2025110507050968000_34.178.250038.101","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-4362.2000.00916.x"},{"key":"2025110507050968000_34.178.250038.102","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1994.00420120079009"},{"key":"2025110507050968000_34.178.250038.103","doi-asserted-by":"crossref","first-page":"596","DOI":"10.5694\/j.1326-5377.1992.tb137399.x","article-title":"Mycobacterium marinum infection: epidemiology and presentation in Queensland 1971\u20131990","volume":"157","author":"Iredell","year":"1992","journal-title":"Med J Aust"},{"key":"2025110507050968000_34.178.250038.104","unstructured":"Woods GL , Brown-Elliott BA , Conville PS , et al. Susceptibility Testing of Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes. Wayne, Clinical and Laboratory Standards Institute, 2011."},{"key":"2025110507050968000_34.178.250038.105","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1684\/ejd.2013.2103","article-title":"Aquarium-borne Mycobacterium marinum skin infection. Report of 15 cases and review of the literature","volume":"23","author":"Bonamonte","year":"2013","journal-title":"Eur J Dermatol"},{"key":"2025110507050968000_34.178.250038.106","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.162.15.1746"},{"key":"2025110507050968000_34.178.250038.107","doi-asserted-by":"publisher","DOI":"10.1136\/emj.14.6.398"},{"key":"2025110507050968000_34.178.250038.108","doi-asserted-by":"publisher","DOI":"10.1016\/S0363-5023(87)80018-7"},{"key":"2025110507050968000_34.178.250038.109","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1986.00360170104017"},{"key":"2025110507050968000_34.178.250038.110","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1977.01640080069009"},{"key":"2025110507050968000_34.178.250038.111","first-page":"96","article-title":"Drug resistance in nontuberculous mycobacteria: mechanisms and models","volume":"10","author":"Saxena","year":"2021","journal-title":"Biology (Basel)"},{"key":"2025110507050968000_34.178.250038.112","doi-asserted-by":"crossref","first-page":"909274","DOI":"10.3389\/fmicb.2022.909274","article-title":"The impact of nontuberculous mycobacteria species on mortality in patients with nontuberculous mycobacterial lung disease","volume":"13","author":"Wang","year":"2022","journal-title":"Front Microbiol"},{"key":"2025110507050968000_34.178.250038.113","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1164\/rccm.202004-1418OC","article-title":"BACES score for predicting mortality in nontuberculous mycobacterial pulmonary disease","volume":"203","author":"Kim","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"2025110507050968000_34.178.250038.114","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s12929-020-00667-6","article-title":"Of tuberculosis and non-tuberculous mycobacterial infections \u2013 a comparative analysis of epidemiology, diagnosis and treatment","volume":"27","author":"Gopalaswamy","year":"2020","journal-title":"J Biomed Sci"},{"key":"2025110507050968000_34.178.250038.115","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ijmyco.2014.11.065","article-title":"Nontuberculous mycobacteria pathogenesis and biofilm assembly","volume":"4","author":"Sousa","year":"2015","journal-title":"Int J Mycobacteriol"},{"key":"2025110507050968000_34.178.250038.116","unstructured":"US Food and Drug Administration . NUZYRA (omadacycline), for injection, for intravenous use NUZYRA (omadacycline) tablets, for oral use. Prescribing information. Date last updated: 2018. Date last accessed: May 2025. www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/209816_209817lbl.pdf"},{"key":"2025110507050968000_34.178.250038.117","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01135-17"},{"key":"2025110507050968000_34.178.250038.118","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.9.3903-3909.2005"},{"key":"2025110507050968000_34.178.250038.119","doi-asserted-by":"crossref","first-page":"e0063824","DOI":"10.1128\/aac.00638-24","article-title":"Omadacycline powder for research procured from unauthorized commercial vendors may be impure and\/or unstable","volume":"68","author":"Serio","year":"2024","journal-title":"Antimicrob Agents Chemother"}],"container-title":["European Respiratory Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/16000617.0038-2025","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T15:05:24Z","timestamp":1762355124000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/16000617.0038-2025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":119,"journal-issue":{"issue":"178","published-online":{"date-parts":[[2025,11,5]]},"published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1183\/16000617.0038-2025"],"URL":"https:\/\/doi.org\/10.1183\/16000617.0038-2025","relation":{},"ISSN":["0905-9180","1600-0617"],"issn-type":[{"value":"0905-9180","type":"print"},{"value":"1600-0617","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10]]}}}